Seven years of PARTNER 3: the evolution of a lifetime valve strategy, reassurance and residual uncertainty

Few advances in cardiovascular medicine have transformed clinical practice as rapidly as transcatheter aortic valve replacement (TAVR).Initially developed for patients considered inoperable or at prohibitive surgical risk, TAVR has progressively expanded into high-, intermediate-, and ultimately low-risk populations (1,2).The question has been whether long-term outcomes and durability can truly match those achieved with surgical aortic valve replacement (SAVR) rather than whether TAVR works.This concern is not unfounded.Surgical valves are implanted under direct visualization with leaflets maintained in their native configuration, whereas transcatheter valves require leaflet crimping before deployment.For more than a decade, this difference has fueled concerns about accelerated structural deterioration, higher reintervention rates, or reduced durability relative to surgical bioprosthesis (3).Earlier-generation valves such as the SAPIEN XT did show higher structural valve deterioration than surgery at 5 years, although the third-generation SAPIEN 3 did not (4).The 7-year report of PARTNER 3, published by Leon and colleagues, is the most robust long-term randomized comparison of balloon-expandable TAVR and SAVR in low-risk patients to date and will likely guide practice until the planned 10-year follow-up (5).The primary composite endpoints were similar, valve durability remained comparable, and patient-reported health status was favorable in both arms.At first glance, these findings appear to establish equivalence, but closer examination suggests a more nuanced conclusion.The most important contribution of PARTNER 3 is not that TAVR and surgery are identical, but that the anticipated durability penalty of TAVR has not emerged through 7 years while mortality has remained comparable.These conclusions remain conditional on long-term event trajectories, differential follow-up completeness, and the potential consequences of device-specific complications.Together, these considerations reestablish the importance of lifetime planning for patients with severe aortic stenosis (6).